-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, the new crown pneumonia is still spreading globally, and vaccines are still one of the most effective ways to control the new crown epidemic
On November 12, Reco Bio released the phased data of the New Zealand phase I clinical trial of the new coronary pneumonia vaccine ReCOV
"Preliminary results suggest that the ReCOV recombinant two-component protein vaccine can induce neutralizing antibodies similar to or higher than the mRNA vaccine, indicating that ReCOV can have a good preventive effect on diseases caused by SARS-CoV-2 infection
It is understood that the ReCOV vaccine was jointly developed by the Jiangsu Provincial Center for Disease Control and Prevention, Taizhou Pharmaceutical High-tech Industrial Park, and Reco Bio.
Professor Zhu Fengcai said that after receiving two doses of 20μg of ReCOV vaccine, the neutralizing antibody level data exceeded expectations.
"The neutralizing antibody of the new crown is the most important indicator for evaluating the protective efficacy of the new crown vaccine.
The new crown vaccine ReCOV uses a unique antigen structure design and new adjuvants
In terms of safety and tolerability, the interim data from the Phase I clinical trial of ReCOV in New Zealand showed that neither SAE (serious adverse events) or TEAEs that led to early withdrawal from the study were reported in high and low dose ReCOV groups in adult and elderly subjects.
It is understood that 360biolabs, the central laboratory for the phase data testing of the ReCOV New Zealand Phase I clinical trial, is a leading comprehensive professional laboratory in Australia and New Zealand, and has passed ISO/IEC 17025, ISO/IEC 15189 and OECD GLP, etc.
Dr.
Professor Zhu Fengcai believes: "As far as the new crown epidemic is concerned, if more effective vaccines can be used to better control the epidemic, then the role of therapeutic drugs is to check for missing and help a small number of patients, rather than play a decisive role
According to the ongoing stability studies of Reco Bio, ReCOV can be stable at room temperature for at least 6 months, while it is expected to remain stable for at least 24 months under standard cold chain conditions
Ruike Biotech stated that it will launch follow-up large-scale clinical trials involving multiple countries around the world as soon as possible to further evaluate the effectiveness and safety of ReCOV; the company plans to submit EUA (emergency authorization for use) or in the second or third quarter of 2022 Conditional listing application
